112P Pseudoprogression predicts better prognosis in advanced non-small cell lung cancer treated with immune checkpoint inhibitors

This is the authors' abstract. We don't add key points for this paper.

Pseudoprogression (PSP) is an initial increase in the size of the primary tumor or the appearance of the new lesions followed by a distinct decrease in tumor burden. Herein, we aimed to evaluate the effect of PSP on treatment response in patients with advanced non-small cell lung cancer (NSCLC).